These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 3729354)

  • 41. Antimicrobial activity in vitro of cefaclor, a new oral cephalosporin.
    Meyers BR; Hirschman SZ
    J Clin Pharmacol; 1978; 18(2-3):85-90. PubMed ID: 624778
    [TBL] [Abstract][Full Text] [Related]  

  • 42. In vitro evaluation of tigemonam, a novel oral monobactam.
    Tanaka SK; Summerill RA; Minassian BF; Bush K; Visnic DA; Bonner DP; Sykes RB
    Antimicrob Agents Chemother; 1987 Feb; 31(2):219-25. PubMed ID: 3105448
    [TBL] [Abstract][Full Text] [Related]  

  • 43. In vitro activity of BAY v 3522, a new oral cephalosporin tested against Haemophilus influenzae and Branhamella catarrhalis.
    Doern GV; Tubert TA
    Diagn Microbiol Infect Dis; 1990; 13(4):349-52. PubMed ID: 2127558
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Activity of different antimicrobial agents against penicillin-resistant Streptococcus pneumoniae].
    Calvo A; Amores R; Valero E; Sevillano D; Prieto J;
    Rev Esp Quimioter; 2001 Dec; 14(4):345-50. PubMed ID: 11856980
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparative in vitro activity of five quinoline derivatives and five other antimicrobial agents used in oral therapy.
    Hoogkamp-Korstanje JA
    Eur J Clin Microbiol; 1984 Aug; 3(4):333-8. PubMed ID: 6237901
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cefetamet pivoxil: comparable evaluation with other orally available antibiotics against selected species of respiratory pathogens.
    Speciale A; Caccamo F; Blandino G; Giacchi GT; Aleo G; Nicoletti G
    Chemotherapy; 1996; 42(1):1-10. PubMed ID: 8751262
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Antimicrobial activity of RU29246 (HR916 metabolite) compared with four other oral beta-lactams tested against more than 5000 clinical isolates.
    Murray PR; Allen SD; Erwin ME; Gerlach EH; Jones RN; Koontz FP; Pfaller MA; Washington JA
    Eur J Clin Microbiol Infect Dis; 1991 Sep; 10(9):776-81. PubMed ID: 1810737
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparable evaluation of orally active beta-lactam compounds in ampicillin-resistant gram-positive and gram-negative rods: role of beta-lactamases on resistance.
    Cullmann W; Dick W; Stieglitz M; Opferkuch W
    Chemotherapy; 1988; 34(3):202-15. PubMed ID: 3262045
    [TBL] [Abstract][Full Text] [Related]  

  • 49. In vitro activity of BMY-28100, a new oral cephalosporin.
    Eliopoulos GM; Reiszner E; Wennersten C; Moellering RC
    Antimicrob Agents Chemother; 1987 Apr; 31(4):653-6. PubMed ID: 3496846
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Review of in vitro activity of third-generation cephalosporins and other newer beta-lactam antibiotics against clinically important bacteria.
    Thornsberry C
    Am J Med; 1985 Aug; 79(2A):14-20. PubMed ID: 3927723
    [TBL] [Abstract][Full Text] [Related]  

  • 51. In vitro evaluation of Ro 09-1227, a novel catechol-substituted cephalosporin.
    Jones RN; Erwin ME
    Antimicrob Agents Chemother; 1992 Jan; 36(1):233-8. PubMed ID: 1590695
    [TBL] [Abstract][Full Text] [Related]  

  • 52. In vitro activity of cefpodoxime compared with other oral cephalosporins tested against 5556 recent clinical isolates from five medical centers.
    Sader HS; Jones RN; Washington JA; Murray PR; Gerlach EH; Allen SD; Erwin ME
    Diagn Microbiol Infect Dis; 1993; 17(2):143-50. PubMed ID: 8243035
    [TBL] [Abstract][Full Text] [Related]  

  • 53. In vitro activities of the novel cephalosporin LB 11058 against multidrug-resistant Staphylococci and Streptococci.
    Sader HS; Johnson DM; Jones RN
    Antimicrob Agents Chemother; 2004 Jan; 48(1):53-62. PubMed ID: 14693518
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Ceftibuten: a new orally absorbed cephalosporin. In vitro activity against strains from the United Kingdom.
    Wise R; Andrews JM; Ashby JP; Thornber D
    Diagn Microbiol Infect Dis; 1991; 14(1):45-52. PubMed ID: 2013210
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Ro 13-9904, a long-acting broad-spectrum cephalosporin: in vitro and in vivo studies.
    Angehrn P; Probst PJ; Reiner R; Then RL
    Antimicrob Agents Chemother; 1980 Dec; 18(6):913-21. PubMed ID: 6972194
    [TBL] [Abstract][Full Text] [Related]  

  • 56. In-vitro activity of cefpodoxime proxetil (RU 51807): a comparative disk diffusion study on isolates from geriatric patients.
    Ottomano C; Frugoni S; Berlusconi A; Miseferi G; Mattina R; Anelli M
    J Chemother; 1991 Jan; 3 Suppl 1():62-5. PubMed ID: 12041788
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Comparison of pharmacokinetics/pharmacodynamics of cefdinir, cefpodoxime proxetil and cefaclor against common bacteria of community acquired infections].
    Xiao YH; Gao L; Li Y; Lü Y; Liu J; Liu Y
    Zhonghua Yi Xue Za Zhi; 2004 Nov; 84(22):1867-71. PubMed ID: 15631795
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Results from the Survey of Antibiotic Resistance (SOAR) 2014-16 in Russia.
    Torumkuney D; Mayanskiy N; Edelstein M; Sidorenko S; Kozhevin R; Morrissey I
    J Antimicrob Chemother; 2018 Apr; 73(suppl_5):v14-v21. PubMed ID: 29659881
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparative antibacterial activity of the new oral cephalosporin BMY-28100.
    Kayser FH
    Eur J Clin Microbiol; 1987 Jun; 6(3):309-12. PubMed ID: 3497804
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparative in vitro activity of the new oral cephalosporin BMY-28100.
    Aldridge KE; Schiro DD; Sanders CV
    Eur J Clin Microbiol; 1987 Apr; 6(2):170-2. PubMed ID: 3595580
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.